Search research articles
Contact Us
Filters
Showing results (21-30 of 145) with videos related to
Page
of 15
Sort By:
Vaccines
|
April 27, 2026
Comparison of Vaccine Platforms for Machupo Virus
Rachel Erickson, Hiromi Muramatsu, Sachchidanand Tiwari, et al.
BMC Molecular Biology
|
June 14, 2008
TATA binding protein associated factor 3 (TAF3) interacts with p53 and inhibits its function
Orsolya Bereczki, Zsuzsanna Ujfaludi, Norbert Pardi, et al.
The Journal of Biological Chemistry
|
October 16, 2007
Daxx-like protein of Drosophila interacts with Dmp53 and affects longevity and Ark mRNA level
László Bodai, Norbert Pardi, Zsuzsanna Ujfaludi, et al.
Molecular Therapy. Nucleic Acids
|
August 27, 2024
The roles of CD4<sup>+</sup> T cell help, sex, and dose in the induction of protective CD8<sup>+</sup> T cells against a lethal poxvirus by mRNA-LNP vaccines
Samita Kafle, Brian Montoya, Lingjuan Tang, et al.
Science Translational Medicine
|
January 10, 2020
Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice
Elinor Willis, Norbert Pardi, Kaela Parkhouse, et al.
Vaccine
|
October 12, 2020
Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine
Philip C LaTourette, Sita Awasthi, Angela Desmond, et al.
Bio-Protocol
|
November 1, 2021
Transient yet Robust Expression of Proteins in the Mouse Liver via Intravenous Injection of Lipid Nanoparticle-encapsulated Nucleoside-modified mRNA
Elissa Everton, Fatima Rizvi, Anna R Smith, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
February 8, 2022
Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine
Hiromi Muramatsu, Kieu Lam, Csaba Bajusz, et al.
Plos Pathogens
|
July 28, 2020
An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection
Kevin P Egan, Lauren M Hook, Alexis Naughton, et al.
Antibodies (Basel, Switzerland)
|
July 25, 2023
Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy
Christopher Chung, Sagar B Kudchodkar, Curtis N Chung, et al.
Page
of 15
Search research articles
Search
Showing results (21-30 of 145) with videos related to
Sort By:
Page
of 15
Vaccines
|
April 27, 2026
Comparison of Vaccine Platforms for Machupo Virus
Rachel Erickson, Hiromi Muramatsu, Sachchidanand Tiwari, et al.
BMC Molecular Biology
|
June 14, 2008
TATA binding protein associated factor 3 (TAF3) interacts with p53 and inhibits its function
Orsolya Bereczki, Zsuzsanna Ujfaludi, Norbert Pardi, et al.
The Journal of Biological Chemistry
|
October 16, 2007
Daxx-like protein of Drosophila interacts with Dmp53 and affects longevity and Ark mRNA level
László Bodai, Norbert Pardi, Zsuzsanna Ujfaludi, et al.
Molecular Therapy. Nucleic Acids
|
August 27, 2024
The roles of CD4<sup>+</sup> T cell help, sex, and dose in the induction of protective CD8<sup>+</sup> T cells against a lethal poxvirus by mRNA-LNP vaccines
Samita Kafle, Brian Montoya, Lingjuan Tang, et al.
Science Translational Medicine
|
January 10, 2020
Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice
Elinor Willis, Norbert Pardi, Kaela Parkhouse, et al.
Vaccine
|
October 12, 2020
Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine
Philip C LaTourette, Sita Awasthi, Angela Desmond, et al.
Bio-Protocol
|
November 1, 2021
Transient yet Robust Expression of Proteins in the Mouse Liver via Intravenous Injection of Lipid Nanoparticle-encapsulated Nucleoside-modified mRNA
Elissa Everton, Fatima Rizvi, Anna R Smith, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
February 8, 2022
Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine
Hiromi Muramatsu, Kieu Lam, Csaba Bajusz, et al.
Plos Pathogens
|
July 28, 2020
An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection
Kevin P Egan, Lauren M Hook, Alexis Naughton, et al.
Antibodies (Basel, Switzerland)
|
July 25, 2023
Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy
Christopher Chung, Sagar B Kudchodkar, Curtis N Chung, et al.
Page
of 15